Affinium Pharmaceuticals announced this week that, in conjunction with its Phase 1 trial of a new antibiotic for treatment of Staphylococcal Infections, it has raised a new round of financing from its current investors. Financial terms were not disclosed, but Toronto-based Affinium is venture-backed by Forward Ventures, the Ontario Emerging Technologies Fund, SV Life Sciences, and Genesis Capital Corporation, according to an earlier story by peHUB.
